FAQ

Cyclin Dependent Kinase Inhibitor P276

Known as: P276 
 

Topic mentions per year

Topic mentions per year

2007-2015
02420072015

Related topics

Related topics

1 relation
P276-00

Related mentions per year

Related mentions per year

2007-2016
20002005201020152020
Cyclin Dependent Kinase Inhibitor P276
P276-00

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Identification of human leukemia antigen A*0201-restricted epitopes derived from epidermal growth factor pathway substrate number 8
T-cell-mediated immunotherapy of hematological malignancies requires selection of targeted tumor-associated antigens and T-cell… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung…
BACKGROUND P276-00 is a novel cyclin-dependent kinase (CDK) inhibitor is in Phase II clinical trials. Valproic acid (VPA), an… (More)
Is this relevant?
2013
2013
P276: Impact of nosocomial infection prevention program at departmental hospital center of Zou Collines, Benin
Methods From April 2004 for a period of six years (2004-2010), we conducted an annual one day prevalence study of NI, preceded by… (More)
Is this relevant?
2012
2012
Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells
Background:Hypoxia-inducible factor-1 (HIF-1) is a master regulator of the transcriptional response to oxygen deprivation and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells
In the present study, we show that the combination of doxorubicin with the cyclin-dependent kinase inhibitor P276-00 was… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 5
Is this relevant?
2012
2012
CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
Despite advances in molecular pathogenesis, pancreatic cancer remains a major unsolved health problem. It is a rapidly invasive… (More)
Is this relevant?
2012
2012
Molecular mechanisms of anti-tumor properties of P276-00 in head and neck squamous cell carcinoma
Tumors of the head and neck present aggressive pathological behavior in patients due to high expression of CDK/CCND1 proteins… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
Preclinical Development CDK-4 Inhibitor P276 Sensitizes Pancreatic Cancer Cells to Gemcitabine-Induced Apoptosis
Despite advances inmolecular pathogenesis, pancreatic cancer remains amajor unsolved health problem. It is a rapidly invasive… (More)
  • figure 1
  • figure 3
  • figure 5
  • figure 6
Is this relevant?
2007
2007
In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.
Cyclin-dependent kinases (Cdk) and their associated pathways represent some of the most attractive targets for the development of… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2007
2007
P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models.
P276-00, a flavone that inhibits cyclin-dependent kinases, has been identified by us recently as a novel antineoplastic agent. In… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?